<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>6969065</pmcid><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmid">31953405</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmc">6969065</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="publisher-id">14159</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="doi">10.1038/s41467-019-14159-1</article-id></all-ids><extracted-table><table-id>Tab1</table-id><table-label>Table 1</table-label><table-caption>Subject characteristics.</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table 1</label><caption><p>Subject characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>ADNI</th><th>CN-Aβ− (<italic>n</italic> = 28)</th><th>CN-Aβ+ (<italic>n</italic> = 32)</th><th>MCI- Aβ+ (<italic>n</italic> = 21)</th><th/><th><italic>p</italic>-value</th></tr></thead><tbody><tr><td>Age</td><td>74.07 (6.82)</td><td>76.88 (5.86)</td><td>74.86 (7.57)</td><td/><td>0.251</td></tr><tr><td>Sex (m/f)</td><td>12/16</td><td>12/20</td><td>11/10</td><td/><td>0.564</td></tr><tr><td>Education (M/SD)</td><td>16.8 (1.94)</td><td>15.0 (4.56)</td><td>15.62 (2.92)</td><td/><td>0.214</td></tr><tr><td>MMSE (M/SD)</td><td>29.25 (1.02)<sup>c</sup></td><td>28.5 (2.13)<sup>c</sup></td><td>26.53 (4.03)<sup>a,b</sup></td><td/><td>0.010</td></tr><tr><td>ADAS-global (M/SD)</td><td>7.93 (4.27)<sup>c</sup></td><td>12.42 (7.16)<sup>c</sup></td><td>17.61 (10.38)<sup>a,b</sup></td><td/><td>0.001</td></tr><tr><td>ApoE ε4 status (pos/neg)</td><td>5/23</td><td>19/13</td><td>14/7</td><td/><td>0.002</td></tr><tr><td>Global AV45 SUVR(M/SD)</td><td>1.04 (0.04)<sup>b,c</sup></td><td>1.33 (0.21)<sup>a</sup></td><td>1.34 (0.13)<sup>a</sup></td><td/><td>&lt;0.001</td></tr><tr><td>Mean tau-PET follow-up time in years (M/SD)</td><td>1.30 (0.52)</td><td>1.27 (0.46)</td><td>1.37 (0.57)</td><td/><td>0.817</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th>BioFINDER</th><th>CN-Aβ− (<italic>n</italic> = 16)</th><th>CN-Aβ+ (<italic>n</italic> = 16)</th><th>MCI- Aβ+ (<italic>n</italic> = 7)</th><th>AD dementia (<italic>n</italic> = 18)</th><th/></tr></thead><tbody><tr><td>Age</td><td>73.88 (5.32)</td><td>75.44 (6.09)</td><td>72.71 (6.63)</td><td>69.83 (10.48)</td><td>0.192</td></tr><tr><td>Sex (m/f)</td><td>10/6</td><td>6/10</td><td>2/5</td><td>11/7</td><td>0.245</td></tr><tr><td>Education (M/SD)</td><td>12.59 (4.06)</td><td>10.56 (3.22)</td><td>11.14 (2.67)</td><td>13.44 (3.26)</td><td>0.097</td></tr><tr><td>MMSE (M/SD)</td><td>29 (1.1)<sup>d</sup></td><td>29.31 (1.08)<sup>d</sup></td><td>25.57 (2.94)</td><td>22.06 (5.17)<sup>a,b</sup></td><td>&lt;0.001</td></tr><tr><td>ADAS-delayed recall (M/SD)</td><td>1.81 (1.47)<sup>c,d</sup></td><td>2.31 (1.49)<sup>c,d</sup></td><td>6.17 (2.4)</td><td>7.62 (2.45)<sup>a,b</sup></td><td>&lt;0.001</td></tr><tr><td>ApoE ε4 status (pos/neg)</td><td>0/16</td><td>10/6</td><td>4/3</td><td>11/7</td><td>&lt;0.001</td></tr><tr><td>Global Flutemetamol SUVR</td><td>0.52 (0.03)<sup>b,c,d</sup></td><td>0.77 (0.12)<sup>a,d</sup></td><td>0.84 (0.14)<sup>a</sup></td><td>0.97 (0.15)<sup>a,b</sup></td><td>&lt;0.001</td></tr><tr><td>Mean tau-PET follow-up time in years (M/SD)</td><td>2.03 (0.47)</td><td>1.91 (0.32)</td><td>1.82 (0.12)</td><td>1.97 (0.34)</td><td>0.484</td></tr></tbody></table><table-wrap-foot><p>p-values were derived from ANOVA for continuous measures and from Chi-squared tests for categorical measures</p><p><italic>M</italic> male, <italic>f</italic> female, <italic>MMSE</italic> Mini-Mental State Exam, <italic>ADAS</italic> Alzheimer’s disease assessment scale, cognitive subscale</p><p>Mean values significantly (p &lt; 0.05) different from—</p><p><sup>a</sup>CN-Aβ−</p><p><sup>b</sup>CN-Aβ+</p><p><sup>c</sup>MCI-Aβ+</p><p><sup>d</sup>AD dementia</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Subject characteristics.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th>ADNI</th><th>CN-Aβ− (n = 28)</th><th>CN-Aβ+ (n = 32)</th><th>MCI- Aβ+ (n = 21)</th><th/><th>p-value</th></tr></thead><tbody><tr><td>Age</td><td>74.07 (6.82)</td><td>76.88 (5.86)</td><td>74.86 (7.57)</td><td/><td>0.251</td></tr><tr><td>Sex (m/f)</td><td>12/16</td><td>12/20</td><td>11/10</td><td/><td>0.564</td></tr><tr><td>Education (M/SD)</td><td>16.8 (1.94)</td><td>15.0 (4.56)</td><td>15.62 (2.92)</td><td/><td>0.214</td></tr><tr><td>MMSE (M/SD)</td><td>29.25 (1.02)c</td><td>28.5 (2.13)c</td><td>26.53 (4.03)a,b</td><td/><td>0.010</td></tr><tr><td>ADAS-global (M/SD)</td><td>7.93 (4.27)c</td><td>12.42 (7.16)c</td><td>17.61 (10.38)a,b</td><td/><td>0.001</td></tr><tr><td>ApoE ε4 status (pos/neg)</td><td>5/23</td><td>19/13</td><td>14/7</td><td/><td>0.002</td></tr><tr><td>Global AV45 SUVR(M/SD)</td><td>1.04 (0.04)b,c</td><td>1.33 (0.21)a</td><td>1.34 (0.13)a</td><td/><td>&lt;0.001</td></tr><tr><td>Mean tau-PET follow-up time in years (M/SD)</td><td>1.30 (0.52)</td><td>1.27 (0.46)</td><td>1.37 (0.57)</td><td/><td>0.817</td></tr></tbody></table></div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th>BioFINDER</th><th>CN-Aβ− (n = 16)</th><th>CN-Aβ+ (n = 16)</th><th>MCI- Aβ+ (n = 7)</th><th>AD dementia (n = 18)</th><th/></tr></thead><tbody><tr><td>Age</td><td>73.88 (5.32)</td><td>75.44 (6.09)</td><td>72.71 (6.63)</td><td>69.83 (10.48)</td><td>0.192</td></tr><tr><td>Sex (m/f)</td><td>10/6</td><td>6/10</td><td>2/5</td><td>11/7</td><td>0.245</td></tr><tr><td>Education (M/SD)</td><td>12.59 (4.06)</td><td>10.56 (3.22)</td><td>11.14 (2.67)</td><td>13.44 (3.26)</td><td>0.097</td></tr><tr><td>MMSE (M/SD)</td><td>29 (1.1)d</td><td>29.31 (1.08)d</td><td>25.57 (2.94)</td><td>22.06 (5.17)a,b</td><td>&lt;0.001</td></tr><tr><td>ADAS-delayed recall (M/SD)</td><td>1.81 (1.47)c,d</td><td>2.31 (1.49)c,d</td><td>6.17 (2.4)</td><td>7.62 (2.45)a,b</td><td>&lt;0.001</td></tr><tr><td>ApoE ε4 status (pos/neg)</td><td>0/16</td><td>10/6</td><td>4/3</td><td>11/7</td><td>&lt;0.001</td></tr><tr><td>Global Flutemetamol SUVR</td><td>0.52 (0.03)b,c,d</td><td>0.77 (0.12)a,d</td><td>0.84 (0.14)a</td><td>0.97 (0.15)a,b</td><td>&lt;0.001</td></tr><tr><td>Mean tau-PET follow-up time in years (M/SD)</td><td>2.03 (0.47)</td><td>1.91 (0.32)</td><td>1.82 (0.12)</td><td>1.97 (0.34)</td><td>0.484</td></tr></tbody></table></div>p-values were derived from ANOVA for continuous measures and from Chi-squared tests for categorical measuresM male, f female, MMSE Mini-Mental State Exam, ADAS Alzheimer’s disease assessment scale, cognitive subscaleMean values significantly (p &lt; 0.05) different from—aCN-Aβ−bCN-Aβ+cMCI-Aβ+dAD dementia</transformed-table></extracted-table></extracted-tables-set>